HRTX

Heron Therapeutics, Inc.

HRTX | $2.71 -2.17% -2.21% 1.8M

(0.0% 1d) (-6.1% 1m) (2.6% 1y) (0.0% 2d) (-5.5% 3d) (-4.8% 7d) (-5.67% volume)
Earnings Calendar: 2024-03-12
Market Cap: $ 407,390,465
http://www.herontx.com
Sec Filling | Patents | 231 employees

(US) Heron Therapeutics, Inc. is a biotechnology company, which engages in the development of pharmaceutical products for patients suffering from cancer. Its products portfolio include SUSTOL, Cinvanti, HTX-011, and HTX-034. The company was founded in February 1983 and is headquartered in Redwood City, CA.

cancer

Drugs

CINVANTI (aprepitant)
SUSTOL (granisetron)

add to watch list Paper trade email alert is off

Press-releases

Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City
Published: 2024-04-11 (Crawled : 20:00) - prnewswire.com
HRTX | $2.71 -2.17% -2.21% 1.8M

Health Technology

| -5.78% | O: -0.34% H: 4.78% C: -0.68%
day city therapeutics

Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
Published: 2024-03-28 (Crawled : 20:00) - prnewswire.com
HRTX | $2.71 -2.17% -2.21% 1.8M

Health Technology

| Email alert Add to watchlist
conference presentation therapeutics

Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates
Published: 2024-03-12 (Crawled : 20:00) - prnewswire.com
HRTX | $2.71 -2.17% -2.21% 1.8M

Health Technology

| 17.37% | O: 18.64% H: 15.0% C: 7.5%
therapeutics financial results

Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024
Published: 2024-02-28 (Crawled : 13:00) - prnewswire.com
HRTX | $2.71 -2.17% -2.21% 1.8M

Health Technology

| 1.09% | O: 0.73% H: 2.17% C: -2.17%
report year therapeutics financial results

Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures
Published: 2024-01-24 (Crawled : 01:00) - prnewswire.com
HRTX | $2.71 -2.17% -2.21% 1.8M

Health Technology

| 25.91% | O: 5.91% H: 12.45% C: 12.23%
zynrelef fda approval expansion therapeutics

Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF®, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain
Published: 2024-01-07 (Crawled : 00:00) - prnewswire.com
HRTX | $2.71 -2.17% -2.21% 1.8M

Health Technology

| 56.5% | O: 10.73% H: 8.16% C: 6.63%
zynrelef partnership first life sciences therapeutics

Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance
Published: 2023-11-14 (Crawled : 21:00) - prnewswire.com
HRTX | $2.71 -2.17% -2.21% 1.8M

Health Technology

| 412.96% | O: 35.81% H: 24.84% C: 17.26%
therapeutics financial results

Heron Therapeutics to Report Third Quarter 2023 Financial Results On Tuesday, November 14, 2023
Published: 2023-11-07 (Crawled : 21:00) - prnewswire.com
HRTX | $2.71 -2.17% -2.21% 1.8M

Health Technology

| 250.23% | O: 1.15% H: 3.75% C: -10.24%
report therapeutics financial results

Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates
Published: 2023-08-14 (Crawled : 20:00) - prnewswire.com
HRTX | $2.71 -2.17% -2.21% 1.8M

Health Technology

| 83.44% | O: -7.28% H: 20.71% C: 19.64%
therapeutics financial results

Heron Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023
Published: 2023-08-07 (Crawled : 20:00) - prnewswire.com
HRTX | $2.71 -2.17% -2.21% 1.8M

Health Technology

| 63.91% | O: 2.96% H: 0.57% C: -4.02%
report therapeutics financial results

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0000950170-24-042226	4	2024-04-05	2024-04-03	Sell	M	62500	187500
0000950170-24-042226	4	2024-04-05	2024-04-03	Buy	M	62500	248996
0001209191-24-001982	4	2024-01-20	2024-01-19	Buy	A	83685	83685
0001209191-24-001982	4	2024-01-20	2024-01-19	Buy	A	13948	66180
0001209191-24-001981	4	2024-01-20	2024-01-19	Buy	A	83685	83685
0001209191-24-001981	4	2024-01-20	2024-01-19	Buy	A	13948	69230